Patent ID: 11911359
Assignee: PDS BIOTECHNOLOGY CORPORATION
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 5:
6. A pharmaceutical formulation comprising: a liposome and at least one disease-associated antigen and a non-ionic buffer,
wherein the liposome comprises one or more cationic lipids,
wherein the at least one disease-associated antigen consists of at least one tumor-associated antigen, wherein the disease-associated antigen is a protein or peptide,
wherein the one or more cationic lipids consists of a quaternary cationic lipid,
wherein the one or more cationic lipids is in an amount sufficient to both activate the ERK or p38 components of the MAP kinase signaling pathway and to induce the production of reactive oxygen species by at least 1.2-fold but less than 20-fold over baseline levels, and
wherein the pharmaceutical formulation is free of phosphate buffered saline (PBS).